Home

Abbott Laboratories (ABT)

128.68
+1.14 (0.89%)
NYSE · Last Trade: Oct 22nd, 1:28 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close127.54
Open127.62
Bid128.66
Ask128.69
Day's Range127.11 - 128.84
52 Week Range110.86 - 141.23
Volume2,521,893
Market Cap225.30B
PE Ratio (TTM)16.14
EPS (TTM)8.0
Dividend & Yield2.360 (1.83%)
1 Month Average Volume6,288,026

Chart

About Abbott Laboratories (ABT)

Abbott Laboratories is a global healthcare company that specializes in the development of a wide range of medical devices, diagnostics, nutrition products, and pharmaceuticals. The company focuses on innovation to improve patient outcomes and enhance the quality of life for individuals worldwide. Abbott is known for its advancements in areas such as cardiovascular care, diabetes management, and nutrition science, providing essential tools and solutions that support healthcare professionals and patients in managing various health conditions. With a strong commitment to research and development, Abbott continually seeks to address unmet medical needs and contribute to the advancement of healthcare globally. Read More

News & Press Releases

Boston Scientific Soars: Q3 2025 Earnings Beat Ignites Medical Device Market
Boston Scientific (NYSE: BSX) has delivered an exceptional third-quarter 2025 earnings report, significantly surpassing analyst expectations and reinforcing its position as a leading innovator in the medical device industry. The strong performance, highlighted by robust sales growth and an upward revision of full-year guidance, has sent a positive signal to
Via MarketMinute · October 22, 2025
A Look Into Abbott Laboratories Inc's Price Over Earningsbenzinga.com
Via Benzinga · October 22, 2025
The 5 Most Interesting Analyst Questions From Abbott Laboratories’s Q3 Earnings Call
Abbott Laboratories’ third quarter results met Wall Street’s expectations for both revenue and non-GAAP profit, but the market reacted negatively, with shares declining over 4%. Management pointed to double-digit growth in medical devices, led by diabetes care and electrophysiology, as key drivers for the quarter. CEO Robert Ford commented that “recently launched new products generated nearly $5 billion in sales this quarter,” highlighting the contribution of new offerings. However, ongoing headwinds in the diagnostics segment—especially in China—continued to weigh on results, and the company acknowledged competitive challenges in U.S. pediatric nutrition.
Via StockStory · October 22, 2025
U.S. Job Growth Stalls at 0.1%: Echoes of 2009 as Economy Navigates Fragile Labor Market
The U.S. economy is currently grappling with a significant deceleration in job growth, with proprietary data from investment giant Vanguard revealing a meager 0.1% growth rate for seven of the first nine months of 2025, dipping to an even more concerning 0.09% in September. This marks the
Via MarketMinute · October 21, 2025
Abbott Laboratories' October Price Plunge Is a Signal to Buymarketbeat.com
Abbott Laboratories is on track to reach new highs, potentially by early 2026, opening the door for a 30% stock price increase in addition to the dividend.
Via MarketBeat · October 17, 2025
Analyst See Noise In Q3 P&L, Affirms Abbott's Medtech Strengthbenzinga.com
Abbott eyes 10% EPS growth in 2026 with CGM momentum, new nutrition contracts, and medical device launches driving global expansion.
Via Benzinga · October 16, 2025
These Analysts Revise Their Forecasts On Abbott Following Q3 Resultsbenzinga.com
Via Benzinga · October 16, 2025
Earnings Season Fuels Market Optimism Amidst Economic Headwinds
As the Q3 2025 earnings season unfolds, corporate America is delivering a powerful narrative of resilience and growth, significantly influencing overall stock market movements. Despite a complex backdrop of economic uncertainties and geopolitical tensions, stronger-than-expected corporate performances are largely driving a prevailing sense of optimism among investors. This robust earnings
Via MarketMinute · October 16, 2025
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.fool.com
Investors should be able to count on these stocks to deliver steady and growing income over the long term.
Via The Motley Fool · October 16, 2025
ABT Q3 Deep Dive: Q3 Results in Line with Expectations, Product Pipeline and Market Dynamics Shape Outlook
Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 6.9% year on year to $11.37 billion. Its non-GAAP profit of $1.30 per share was in line with analysts’ consensus estimates.
Via StockStory · October 16, 2025
U.S. Stocks End Mixed Amidst Trade Tensions, Dovish Fed Hopes, and Robust Earnings
The U.S. stock market closed with a mixed performance recently, reflecting a complex and dynamic environment where investor sentiment is being pulled in multiple directions. As of October 15, 2025, a critical "tug of war" is underway, with strong corporate earnings and the anticipation of Federal Reserve interest rate
Via MarketMinute · October 15, 2025
Why Abbott Laboratories (ABT) Stock Is Down Today
Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 3.5% in the afternoon session after the company reported third-quarter financial results that met, but did not exceed, Wall Street's expectations. 
Via StockStory · October 15, 2025
Dividend Duo Delights Investors: Meta Platforms and Johnson & Johnson Shine in 2025
In a year marked by evolving market dynamics and a persistent search for both growth and stability, two distinct titans of industry—Meta Platforms (NASDAQ: META) and Johnson & Johnson (NYSE: JNJ)—have emerged as standout performers for dividend-seeking investors. As of October 15, 2025, these companies represent compelling examples of
Via MarketMinute · October 15, 2025
Gold Gains Over 1%; Abbott Shares Fall After Q3 Resultsbenzinga.com
Via Benzinga · October 15, 2025
Bank Earnings Lift Wall Street, Gold Hits $4,200: What's Moving Markets Wednesday?benzinga.com
Wall Street rose on Wednesday, with investor optimism lifted by strong bank and corporate earnings alongside growing expectations for further Federal Reserve rate cuts — keeping trade concerns sidelined for now.
Via Benzinga · October 15, 2025
Wednesday's session: top gainers and losers in the S&P500 indexchartmill.com
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · October 15, 2025
Abbott Laboratories Remains In Favor With London Investment Manager, New Filing Showsfool.com
Via The Motley Fool · October 15, 2025
1 No-Brainer Dividend Stock to Buy and Hold Foreverfool.com
This is about as safe as a dividend can be.
Via The Motley Fool · October 15, 2025
These S&P500 stocks are gapping in today's sessionchartmill.com
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Wednesday to find the gap up and gap down stocks in today's session.
Via Chartmill · October 15, 2025
Abbott Tightens Annual Sales Forecast As Q3 Sales Miss Expectationsbenzinga.com
Abbott stock fell as Q3 sales missed estimates and 2025 earnings guidance was narrowed despite solid growth in medical devices.
Via Benzinga · October 15, 2025
Abbott Laboratories (NYSE:ABT) Reports Q3 In Line With Expectations
Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 6.9% year on year to $11.37 billion. Its non-GAAP profit of $1.30 per share was in line with analysts’ consensus estimates.
Via StockStory · October 15, 2025
Abbott Labs Skids On Mixed Third-Quarter Report, But One Segment Shinedinvestors.com
Notably, the company reaffirmed its sales guidance and the midpoint of its earnings outlook.
Via Investor's Business Daily · October 15, 2025
What's going on in today's pre-market session: S&P500 moverschartmill.com
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Via Chartmill · October 15, 2025
Abbott Laboratories (NYSE:ABT) Trims 2025 Outlook After Q3 Earningschartmill.com
Abbott Labs Q3 2025 results met EPS views, but trimmed full-year guidance. Sales grew 6.9% as the healthcare giant navigates a complex market.
Via Chartmill · October 15, 2025
Stock Market Today: Nasdaq, Dow Jones Futures Rise, Bank Of America, Morgan Stanley, Abbott In Focus—Analyst Warns US 'Going Broke Slowly'benzinga.com
U.S. stock futures advanced on Wednesday following Tuesday’s mixed close. Futures of major benchmark indices were higher.
Via Benzinga · October 15, 2025